Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Perrigo Company plc (PRGO) vs Supernus Pharmaceuticals, Inc. (SUPN)

Perrigo Company plc and Supernus Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Supernus Pharmaceuticals, Inc. is the larger, with a market value of $2.5B against $2.1B — 1.2× the size. Supernus Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 24.9% against −4.19%. Supernus Pharmaceuticals, Inc. has the higher net margin (−13.2% vs −41.9%) and the higher return on invested capital (−12.4% vs −18.1%). Across the 19 metrics below, Supernus Pharmaceuticals, Inc. leads on 12 and Perrigo Company plc on 7.

Valuation

Metric PRGO SUPN Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 0.52 2.98 2.25
P/B 0.85 2.40 1.90
Price to free cash flow 16.85 147.92 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 1.22 2.59 2.56
Earnings yield (81.06%) (4.50%) (2.99%)
Free cash flow yield 5.93% 0.68% 0.00%

Profitability

Metric PRGO SUPN Drug Manufacturers Specialty & Generic median
Gross margin 33.26% 88.07% 53.94%
Operating margin (37.71%) (15.71%) 0.00%
Net margin (41.85%) (13.23%) 0.00%
Free cash flow margin 2.88% 2.21% 0.00%
Return on equity (49.65%) (10.49%) (0.40%)
Return on assets (19.60%) (7.82%) (3.32%)
Return on invested capital (18.06%) (12.37%) 0.00%

Growth

Metric PRGO SUPN Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (4.19%) 24.85% 10.01%
EPS growth (last fiscal year) (723.20%) (151.52%) —
Revenue growth, 5-year CAGR 0.79% 6.68% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PRGO SUPN Drug Manufacturers Specialty & Generic median
Debt to equity 1.31 0.00 0.05
Current ratio 2.32 2.08 2.31
Net debt to EBITDA (4.01) (11.12) 0.85

Dividend

Metric PRGO SUPN Drug Manufacturers Specialty & Generic median
Dividend yield 3.42% — 1.70%
Payout ratio — 0.00 0.00

Size

Metric PRGO SUPN Drug Manufacturers Specialty & Generic median
Market cap 2.05b 2.52b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack